The Lancet. Oncology
Elsevier Ltd.
Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care
DOI 10.1016/S1470-2045(20)30242-4, Volume: 21, Issue: 6,

Table of Contents



Jones, Neal, Duffy, Scott, Whitaker, and Brain: Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care

The entire landscape of cancer management in primary care, from case identification to the management of people living with and beyond cancer, is evolving rapidly in the face of the coronavirus disease 2019 (COVID-19) pandemic.1 In a climate of fear and mandated avoidance of all but essential clinical services, delays in patient, population, and health-care system responses to suspected cancer symptoms seem inevitable.

Screening, case identification, and referral in symptomatic cancer diagnosis have all been affected by the COVID-19 pandemic. UK national cancer screening programmes—accounting for approximately 5% of all cancer diagnoses each year—have been suspended.2 Consequently, early diagnoses from screening will be delayed and symptom-based diagnosis of cancer will become more important.3 Unfortunately, postponing screening sends a message to the public and primary care that cancer can wait.

Timely presentation to primary care of patients with symptoms is driven by a combination of appraising symptoms as warranting attention, perceived or actual ability to consult a health-care professional, perceived consequences of seeking help, and priority over competing goals.4 It is probable that patients with well recognised red flag symptoms, such as a new lump or rectal bleeding, will continue to present to primary care. With COVID-19 at the forefront, however, vague cancer symptoms such as fatigue, change in bowel habit, and weight loss might be dismissed by the patient as trivial.5 Respiratory symptoms, including persistent cough, might be attributed to COVID-19 and not acted on. Patients might be reluctant to present because of fear of interacting with others, limited capacity to use video or teleconsultations, and concerns about wasting the doctor's time.6, 7

For family doctors, the COVID-19 pandemic is affecting all aspects of normal working life, including a reduced workforce due to illness and self-isolation, and the reduced availability of appointments and investigations in primary and secondary care. The huge shift to telephone triage and video consultations might result in missed cues, reduced examination findings, and loss of the clinician's gut feeling. Remote consulting might also be less suited to vulnerable patients and individuals from low socioeconomic backgrounds than to patients from high socioeconomic settings, compounding inequalities already apparent in early cancer diagnosis.8 If patients with cancer symptoms do present to primary care, there is no consensus on how they should be managed during the pandemic, or safety-netted. When patients are referred, they are likely to be triaged or delayed.9 For example, the cancellation of all but emergency endoscopy will inevitably prolong the time to diagnosis of gastrointestinal cancers.

Management and follow-up of patients with cancer is also affected by the COVID-19 pandemic. Many patients with cancer, especially those undergoing chemotherapy, radical radiotherapy, and immunotherapy, are at greater risk from the symptoms and sequelae of COVID-19. The National Health Service guidelines state that patients will want to discuss whether the benefits of continuing active cancer treatment outweigh the risks of potentially being seriously unwell if they contract COVID-19, which is a role that could well fall to primary care.9 The UK cancer charity Macmillan Cancer Support reports that a quarter of calls to its support line are from patients with cancer who are anxious about COVID-19.10 Although cancer charities provide a vital support role, primary care needs to support the physical and mental health of patients for whom potentially lifesaving cancer treatments are being postponed.

Cancer treatments are a priority in the health-care system, but as health-care become increasingly occupied with caring for patients with COVID-19, these patients will inevitably take precedence. Patients needing immediate care are receiving treatment, but when possible, treatments will be delayed. Guidance to help make these difficult decisions might be variable, inconsistent, and hurried, with the inevitable risk to patient outcomes. In this situation, the psychological effect on patients and clinical staff will be enormous.

The COVID-19 pandemic has implications for primary care and the crisis has highlighted potential solutions for dealing with future global health threats. Although these are unprecedented times, it is probable that the use of remote consultations will grow. Increased flexibility in accessing health care might serve to advantage some population groups, but risks disadvantaging others. If done well, remote consulting could benefit previously underserved patient populations (ie, individuals living in remote areas).

Behavioural interventions to encourage the timely symptomatic diagnosis of cancer are important. Public awareness campaigns should signal that early help-seeking is welcome and legitimate, and might use social media and community networks that have grown in response to COVID-19. Clinicians should be aware of so-called diagnostic overshadowing from COVID-19 and remember that patients might have markedly delayed presentation already and need additional support navigating the next steps in terms of their referral and safety-netting.

If cancer is suspected, clinicians should not be deterred from referring patients urgently because of COVID-19 or other future global health threats. However, health-care professionals might have to accept triage and risk stratification of patients with potentially serious disease. Biomarker and machine-learning approaches might support prioritisation of patients who are at greatest risk, diverting health-care resources towards managing patients who are seriously ill.

When patients are diagnosed with cancer, or are living with or beyond cancer, providers of primary care might have to accept enhanced roles in supporting decisions on cancer treatment, palliative care, and advanced planning around resuscitation and preferred places of care.

When normal service resumes at a population and health-service level, there will be a huge backlog of patients with potential cancer symptoms needing urgent assessment. Planning for recovery should commence as soon as possible.



    The Lancet Oncology. COVID-19: global consequences for oncology. Lancet Oncol 21: 2020. , pp.467


    National Cancer Registration and Analysis Service. Routes to diagnosis.,


    Hamilton W, Walter FM, Rubin G, Neal RD. Improving early diagnosis of symptomatic cancer. Nat Rev Clin Oncol 13: 2016. , pp.740-749


    Scott SE, Walter FM, Webster A, Sutton S, Emery J. The model of pathways to treatment: conceptualization and integration with existing theory. Br J Health Psychol 18: 2013. , pp.45-65


    Whitaker KL, Scott SE, Winstanley K, Macleod U, Wardle J. Attributions of cancer ‘alarm’ symptoms in a community sample. PLoS One 9: 2014. , pp.1-17


    Forbes LJL, Simon AE, Warburton F. Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival?. Brit J Cancer 108: 2013. , pp.292-300


    Llanwarne N, Newbould J, Burt J, Campbell JL, Roland M. Wasting the doctor's time? A video-elicitation study with patients in primary care. Soc Sci Med 176: 2017. , pp.113-122


    Public Health England. COVID-19: Guidance for health professionals., April 23, 2020.


    Public Health England. Clinical guide for the management of noncoronavirus patients requiring acute treatment: cancer., March 23, 2020.


    Extance A. Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease?. BMJ 368: 2020. m1174


We declare no competing interests. This research is linked to the CanTest Collaborative, which is funded by Cancer Research UK (C8640/A23385), of which RDN is an associate director and SES is a co-investigator. It also comes under the auspices of the Health and Care Research Wales funded Primary and Emergency Care Research Centre (517195) and Wales Cancer Research Centre (517190), in which KB is co-investigator and collaborator. of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care&author=Daniel Jones,Richard D Neal,Sean R G Duffy,Suzanne E Scott,Katriina L Whitaker,Kate Brain,&keyword=&subject=Comment,